Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Raw Materials (2023 - 2025)

Verrica Pharmaceuticals (VRCA) has 3 years of Raw Materials data on record, last reported at $1.0 million in Q2 2025.

  • For Q2 2025, Raw Materials fell 12.27% year-over-year to $1.0 million; the TTM value through Jun 2025 reached $1.0 million, down 12.27%, while the annual FY2024 figure was $1.1 million, 157.62% up from the prior year.
  • Raw Materials reached $1.0 million in Q2 2025 per VRCA's latest filing, down from $1.0 million in the prior quarter.
  • Across five years, Raw Materials topped out at $1.2 million in Q3 2024 and bottomed at $116000.0 in Q3 2023.
  • Average Raw Materials over 3 years is $897375.0, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Raw Materials: skyrocketed 941.38% in 2024, then dropped 12.27% in 2025.
  • A 3-year view of Raw Materials shows it stood at $420000.0 in 2023, then soared by 157.62% to $1.1 million in 2024, then decreased by 6.84% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $1.0 million in Q2 2025, $1.0 million in Q1 2025, and $1.1 million in Q4 2024.